PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629180
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629180
Diabetic gastroparesis market size was valued at USD 1,974.90 Million in 2023, expanding at a CAGR of 4.30% from 2024 to 2032.
Diabetic Gastroparesis is a digestive disorder where diabetes damages the vagus nerve, slowing stomach muscle function. This impairs stomach emptying, causing food to remain longer than normal, leading to symptoms like nausea, bloating, vomiting, and fluctuating blood sugar levels. It is common in individuals with long-term or poorly controlled diabetes, particularly type 1. Managing it involves dietary adjustments, blood sugar control, and, in some cases, medications or other therapies.
Diabetic Gastroparesis Market- Market Dynamics
Rising prevalence of diabetes to surge the market demand
The increasing number of diabetes cases is driving market demand, with International Diabetes federation reporting 537 million global diabetes cases as of 2021. Besides, an aging population and lifestyle changes contribute to more diabetes and gastroparesis cases, expanding the market for related treatments. However, limited awareness among diabetic patients about gastroparesis restricts early diagnosis and treatment, affecting market growth. On the contrary, continuous innovation in gastroparesis drug therapies offers promising opportunities for the global diabetic gastroparesis market growth. Furthermore, the rising geriatric population worldwide increases the demand for effective gastroparesis treatments, especially for elderly diabetes patients.
Diabetic Gastroparesis Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.30% over the forecast period (2024-2032)
Based on types segmentation, grade 3 was predicted to show maximum market share in the year 2023
Based on treatment segmentation, pharmacological treatment was the leading segment in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Diabetic Gastroparesis Market is segmented on the basis of Types, Treatment, Distribution Channel, and Region.
The market is divided into two categories based on types: grade 3 (gastric failure) and grade 2 (compensated gastroparesis). The grade 3 (gastric failure) sector dominates the market. The severe nature of this condition, which demands more intensive treatment and management options is driving higher demand in the market.
The market is divided into two categories based on treatment: surgery and pharmacological treatment. The pharmacological treatment sector dominates the market and is likely to maintain its dominance during the forecast period. It offers less invasive options compared to surgery and includes a range of drugs like prokinetics and antiemetics, which are effective in symptom management.
Diabetic Gastroparesis Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
The global market is expanding due to rising cases of diabetes and the demand for targeted treatment options. Companies are focusing on developing innovative therapies that address gastroparesis symptoms effectively, alongside improving drug formulations to enhance patient adherence. Strategic collaborations, clinical trials, and R&D investments are core strategies employed to bring novel treatments to market, while some companies explore regional partnerships to improve access in emerging markets and optimize distribution networks.
In June 2024, Renexxion Ireland Limited received FDA approval for an Investigational New Drug (IND) application for naronapride, an oral medication designed to treat gastroparesis. This promising drug aims to address symptoms associated with slow gastric emptying, such as nausea and vomiting, advancing treatment options for gastrointestinal disorders.